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Decreased Expression of Caveolin-1 Contributes to
the Pathogenesis of Psoriasiform Dermatitis in Mice
Yukie Yamaguchi1, Yuko Watanabe1, Tomoya Watanabe1, Noriko Komitsu1 and Michiko Aihara1
Psoriasis is a chronic inﬂammatory skin disease characterized by excessive proliferation and abnormal
keratinocyte development, in which T helper type 17 cells and signal transducer and activator of transcription 3
(STAT3) activation have pivotal roles. Moreover, caveolin-1 (CAV-1) has been implicated in the regulation of
signal transduction, and aberrant CAV-1 expression is involved in a variety of diseases. However, whether CAV-1
is involved in psoriasis is unknown. Here we examined CAV-1 expression in the psoriatic epidermis and
investigated its role in the pathogenesis of psoriasis. CAV-1 was markedly reduced in lesional epidermis of
psoriasis patients. CAV1 silencing in keratinocytes in vitro revealed signiﬁcant activation of STAT3, leading to
increased expression of keratin 16 and several cytokine/chemokines, such as IL-6, C-X-C chemokine ligand 8
(CXCL8), CXCL9, and C-C chemokine ligand 20. In addition, psoriasis-related cytokines, including tumor necrosis
factor-α (TNF-α), decreased CAV-1 expression in keratinocytes. Finally, administration of CAV-1 scaffolding
domain peptide in a murine model of psoriasis-like skin inﬂammation induced by imiquimod improved the skin
phenotype and reduced epidermal thickness and inﬁltrating cell counts. Furthermore, expression of TNF-α,
IL-17A, and IL-23 was signiﬁcantly suppressed by this treatment. Collectively, our study indicated that CAV-1
participates in the pathogenesis of psoriasis by regulating the STAT3 pathway and cytokine networks.
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INTRODUCTION
Psoriasis vulgaris is a chronic immune-mediated inﬂammatory
skin disease characterized by scaly papulosquamous plaque
lesions (Grifﬁths and Barker, 2007). Innate effector cells
present in psoriatic lesions, including dendritic cells and T
helper type 17 cells, have key roles in the initial stages and
also in the later amplifying inﬂammatory stages of psoriasis
(Lowes et al, 2007; Nestle et al, 2009). In the chronic phase,
various cytokines produced by inﬁltrated dendritic cells and
T cells, such as tumor necrosis factor (TNF)-α, IL-17, and
IL-22, induce hyperproliferation and keratinocyte activation
via phosphorylation of signal transducer and activator of
transcription 3 (STAT3). Activated keratinocytes also produce
growth factors and cytokines/chemokines, causing further
inﬂammation, epithelial–stromal hyperplasia, and immune
cell mobilization (Nograles et al., 2010). Thus, a vicious cycle
of inﬂammatory cytokines/chemokines triggering leukocyte
inﬁltration, activation, and keratinocyte proliferation is
produced, ultimately resulting in chronic skin lesion
formation (Nickoloff and Nestle, 2004).
Caveolin-1 (CAV-1) is a 22-kDa membrane protein that is
essential for the formation of ﬂask-shaped membrane
invaginations known as caveolae (Yamada, 1955). Caveolae
have a distinctive composition of lipids, including
cholesterol and sphingolipids, and participate in trafﬁcking,
endocytosis, and signaling (Schlegel et al, 2005; Galbiati
et al, 2001; Parton and Richards, 2003). CAV-1 regulates a
variety of signaling molecules and receptors, including SRC,
SMAD/the transforming growth factor (TGF)-β receptor, the
insulin receptor, AKT, and mitogen-activated protein kinase
(MAPK); these molecules are able to bind to the CAV-1
scaffolding domain (CSD; amino acids 82–101) (Razani
et al, 2001; Stan, 2005; Tourkina et al, 2005). CAV-1 has
been implicated in various human diseases, including
diabetes, cancer, cardiovascular disease, systemic sclerosis,
and pulmonary ﬁbrosis (Wang et al, 2006; Galdo et al, 2008;
Strålfors, 2012; Yamaguchi et al, 2013; Núñez-Wehinger
et al, 2014), in which it is a direct inhibitor of different
plasma-membrane-initiated signaling cascades (Okamoto
et al, 1998).
Campbell et al (2002) proposed participation of CAV-1 in
psoriasis after showing that CAV-1 is downregulated in
chronic plaque psoriasis. On the basis of these initial ﬁndings,
we examined whether CAV-1 is explicitly involved in the
pathogenesis of psoriasis and present evidence indicating that
CAV-1 indeed has an important role in the pathogenesis of
chronic psoriatic inﬂammation.
ORIGINAL ARTICLE
1Department of Environmental Immuno-Dermatology, Yokohama City
University Graduate School of Medicine, Yokohama, Japan
Correspondence: Yukie Yamaguchi, Department of Environmental Immuno-
Dermatology, Yokohama City University Graduate School of Medicine, 3-9
Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004, Japan.
E-mail: yui1783@yokohama-cu.ac.jp
Received 25 January 2015; revised 2 June 2015; accepted 12 June 2015;
accepted article preview online 2 July 2015; published online 20 August 2015
Abbreviations: CAV-1, caveolin-1; CSD, caveolin-1 scaffolding domain; IMQ,
imiquimod; JAK, Janus kinase; KRT16, keratin 16; MAPK, mitogen-activated
protein kinase; STAT, signal transducer and activator of transcription; TGF,
transforming growth factor; TNF, tumor necrosis factor
2764 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
RESULTS
Reduced CAV-1 expression in the epidermis of psoriasis patients
and in a murine model of psoriasis-like skin inﬂammation
We ﬁrst evaluated CAV-1 levels in psoriatic skin. Immuno-
histochemical analysis indicated a marked decrease in CAV-1
expression in the epidermis of psoriasis patients compared
with healthy control subjects (Figure 1a). CAV1 mRNA and
protein levels were also examined in the separated epidermis
of skin samples from patients’ plaque psoriasis lesions and
from healthy control subjects, using semi-quantitative and
quantitative PCR (qPCR) and western blotting. CAV-1 expres-
sion was clearly reduced in the lesions of psoriasis patients
(Figure 1b and c). Consecutive skin biopsy samples contain-
ing both lesional and non-lesional areas indicated that only
lesional skin had reduced CAV-1 levels (Figure 1d).
We then evaluated CAV-1 levels in the epidermis of a
mouse model of psoriasis-like skin inﬂammation, induced
using imiquimod (IMQ), as previously described (van der Fits
et al, 2009). Real-time qPCR and immunohistochemistry indi-
cated that CAV-1 levels were also reduced in the epidermis of
these mice (Figure 1e and f).
Activation of the Janus kinase 2 (JAK2)/STAT3 pathway in
CAV-1-silenced human keratinocytes
Recent studies have shown that CAV-1 negatively modulates
signal transduction by directly binding to signaling molecules,
suggesting that altered CAV-1 expression in different diseases
could contribute to the disease pathogenesis. As direct
interaction of CAV-1 and STAT3 has previously been reported
in different cell types (Medina et al, 2006; Yuan et al, 2011),
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Figure 1. Decreased caveolin-1 (CAV-1) expression in the epidermis of psoriasis. (a) Representative images of immunohistochemical analysis of CAV-1 in the
skin from a psoriasis patient (Pso) and a healthy subject (HC). Scale bar= 100 μm. (b and c) CAV-1 expression was evaluated using semi-quantitative and
quantitative PCR (b) and western blotting (c). (b) Representative semi-quantitative PCR images from three patients and healthy controls are shown. Five individual
samples were subjected to quantitative PCR in duplicate, ***Po0.001. (c) Representative images of immunoblotting were shown. The CAV-1 protein levels were
quantiﬁed using densitometry and expressed as the ratio of CAV-1 to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in c. n=5; **Po0.01. (d) Skin tissue,
which shows adjacent psoriatic lesions and normal skin, was stained with an anti-CAV-1 antibody. Scale bar=300 μm. (e) CAV-1 expression levels in the
epidermis of imiquimod (IMQ)-treated mice were determined by quantitative PCR. n= 6; ***Po0.001. (f) Immunohistochemical analysis of CAV-1 in IMQ-
treated mice skin. Scale bar= 50 μm.
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we conﬁrmed colocalization and binding of CAV-1 and
STAT3 proteins in human keratinocytes. CAV-1 colocalized
with both STAT3 and phosphorylated STAT3 (pSTAT3)
(Figure 2a), and direct interaction was conﬁrmed by
coimmunoprecipitation (Figure 2b), suggesting that CAV-1
may inﬂuence STAT3 signaling.
We hypothesized that reduced CAV-1 activity could
inﬂuence JAK/STAT signal transduction and thereby
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Figure 2. Activation of the signal transducer and activator of transcription 3 (STAT3) pathway in caveolin-1 (CAV-1)-silenced keratinocytes. (a) CAV-1 and
phosphorylated STAT3 (pSTAT3)/STAT3 localization was determined by immunocytochemical staining. Human keratinocytes with or without prior IL-22
stimulation were stained for pSTAT3/STAT3 (green) and CAV-1 (red). DAPI (4,6-diamidino-2-phenylindole; blue) was used to identify nuclei. Scale bars= 20 μm.
(b) Cell lysates from human keratinocytes were immunoprecipitated (IP) with an anti-CAV-1 antibody or control immunoglobulin G (IgG). Coprecipitation of
pSTAT3 or STAT3 was examined by immunoblotting (IB). Non-precipitated sample was loaded and shown as input. Experiments were repeated three times.
(c) CAV-1 was silenced using RNAi. pSTAT3 and pJAK2 were evaluated at the indicated time points after IL-22 stimulation in CAV-1-silenced (siCAV-1) or
control siRNA (siNeg)-treated keratinocytes. Total STAT3 or JAK2 was quantiﬁed as controls. Experiments were performed on three independent occasions.
(d) Protein levels shown in c were quantiﬁed with densitometry and expressed as the ratio of pSTAT3 to STAT3 and pJAK2 to JAK2. The level of each protein at
time 0 was set to 1 arbitrary units. Statistical analysis was performed between siNeg versus siCAV-1 at the each same time point, n= 3; *Po0.05 and **Po0.01.
(e) Transcriptional activity of STAT3 was detected in siCAV-1 or control keratinocytes (siNeg) with IL-22 stimulation using a luciferase STAT3 promoter
assay. Negative promoter was used as control. Three independent experiments were performed. *Po0.05.
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contribute to psoriasis pathogenesis. CAV-1 was knocked
down in human keratinocytes using RNA interference, and
cells were stimulated with IL-22 to induce STAT3 activation.
About 63% reduction in CAV-1 protein was achieved
(Supplementary Figure S1 online). Interestingly, pSTAT3
levels were signiﬁcantly enhanced in CAV-1-silenced kerati-
nocytes compared with those in controls (Figure 2c and d).
Similar augmentation was also observed for pJAK2, an
upstream signaling molecule of STAT3.
We further performed STAT3-dependent luciferase reporter
gene assays to prove the transcriptional activity of STAT3.
Consistent with the immunoblotting data, luciferase activation
was enhanced in CAV-1-silenced keratinocytes compared
with that in the control after IL-22 stimulation (Figure 2e).
Thus, reduction in CAV-1 activity in keratinocytes, as is
observed in psoriatic inﬂammation, activates STAT3. There-
fore, alterations in CAV-1 may exert pathogenic effects in
psoriasis patients.
Increased expression of a proliferation marker, inﬂammatory
cytokines, and chemokines in CAV-1-silenced keratinocytes
Because STAT3 is involved in keratinocyte proliferation and
affects the expression of several cytokines, we hypothesized
that enhanced STAT3 activity in CAV-1-reduced keratino-
cytes could further enhance proliferation and production of
inﬂammatory molecules in keratinocytes. To this end, we
determined the levels of keratin 16 (KRT16), a marker of
keratinocyte hyperproliferation, in CAV-1-silenced keratino-
cytes following IL-22 stimulation. KRT16 mRNA levels were
markedly elevated in CAV-1-reduced keratinocytes compared
with controls (Figure 3a).
Next, we determined the quantity of psoriasis-related
cytokines and chemokines, such as C-X-C chemokine ligand
8 (CXCL8), CXCL9, C-C chemokine ligand 20 (CCL20), and
IL-6, released from keratinocytes; reduced CAV-1 levels
resulted in a marked increase in the quantity of cytokines
and chemokines secreted. Thus, the levels of pSTAT3-
associated cytokine mRNA were shown to be increased, at
least by qPCR (Figure 3b).
Psoriasis-related inﬂammatory cytokines reduce CAV-1
expression in human keratinocytes
Diminished CAV-1 levels in psoriatic keratinocytes likely
contribute to augmentation or maintenance of pathogenic
inﬂammation. However, the trigger for reduced CAV-1 levels
is unclear. Given that reduced CAV-1 levels are only
observed in lesional skin, it is possible that psoriatic
inﬂammation itself causes the reduction in CAV-1 levels. To
investigate this, we examined the effect that psoriasis-related
cytokines exert on CAV-1 expression levels in cultured
keratinocytes treated with IL-17A, IL-22, TNF-α, TGF-β,
epidermal growth factor, or IL-1β. CAV1 mRNA expression
was signiﬁcantly suppressed by the indicated psoriasis-related
cytokines, especially TNF-α, suggesting the possibility that
psoriatic inﬂammation itself may decrease CAV-1 expression
(Figure 3c).
CSD peptide improves the skin phenotype in an IMQ-induced
murine model of psoriasis-like skin inﬂammation
Having veriﬁed the importance of CAV-1 in the chronic
inﬂammation observed in psoriasis, we investigated the effect
of restoring CAV-1 function using a CSD peptide. This is a
membrane-permeable peptide based on the scaffolding
domain of CAV-1, which has previously been shown to
mimic the inhibitory effect of full-length CAV-1 on cellular
signaling (Bucci et al, 2000). We intradermally administered
CSD peptide daily for 7 days, following each IMQ
administration, and evaluated the skin phenotype. The skin
phenotype of IMQ-treated mice was markedly suppressed by
administration of the CSD peptide, as compared with the
control peptide–treated mice (Figure 4a). The clinical skin
scores for erythema, induration, and scale were notably
improved by CSD treatment (Figure 4b). In addition,
histological analysis indicated that the epidermal thickness
and the number of inﬁltrating cells were strikingly reduced in
the CSD peptide–treated mice (Figure 4c–e). In particular, the
number of inﬁltrated CD4+ cells was signiﬁcantly decreased
by CSD treatment, and CD11c+ cells also tended to be
suppressed, although this was not statistically signiﬁcant
(Figure 5a and b).
We also evaluated the expression levels of psoriasis-related
cytokines in the dermis, such as TNF-α, IL-23p19, IL-17A, and
IFN-α. IMQ treatment signiﬁcantly increased the expression
levels of TNF-α, IL-23p19, and IL-17A, which was inhibited
by concomitant CSD treatment (Figure 5c). There was no
difference in IFN-α expression.
Furthermore, pSTAT3-positive cells were clearly dimin-
ished in CSD peptide–treated mice (Figure 5d). Thus these
results demonstrate that administration of the CSD peptide
provides a remarkable degree of protection against IMQ-
induced psoriasis-like skin inﬂammation. Notably, CAV1
mRNA levels were signiﬁcantly higher in CSD peptide–
treated mice than in control peptide–treated mice (Figure 6a).
CAV-1 protein levels also tended to be increased by CSD
peptide treatment (Figure 6b). Taken together, CAV-1 exerts
an important role in the chronic inﬂammation of psoriasis
(Figure 6c). Thus, modifying CAV-1 levels might help combat
the vicious cycle of chronic inﬂammation in psoriasis.
DISCUSSION
Our goal was to evaluate CAV-1 levels in psoriatic skin and to
investigate its role in the pathogenesis of psoriasis. We
observed a signiﬁcant reduction in CAV-1 in the epidermis of
psoriasis patients only in the lesional skin, not in non-lesional
areas, suggesting that reduced CAV-1 may not be a
fundamental trigger of psoriasis but could be directly involved
in the formation or maintenance of psoriatic skin lesions. Our
immunohistological staining consistently showed a signiﬁcant
decrease of CAV-1 within hyperproliferative regions, includ-
ing the basal cell layers but not particularly in the upper
granular layers in psoriasis patients, in agreement with the
ﬁndings by Campbell et al (2002). Further investigation of
the effect of CAV-1 reduction on STAT3 activation and
cytokine/chemokine production in keratinocytes revealed
some pathogenic mechanisms associated with psoriatic
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inﬂammation. More speciﬁcally, elevated KRT16, IL-6,
CXCL8, CXCL9, and CCL20 expression in CAV-1-reduced
keratinocytes would lead to keratinocyte hyperproliferation
and mobilization of neutrophils, T lymphocytes, and dendritic
cells. Furthermore, psoriasis-related cytokines, including TNF-
α, IL-17A, and IL-22, secreted by activated immune cells and
keratinocytes, might trigger further CAV-1 downregulation in
keratinocytes. This ﬁnding is partially supported by previous
studies which indicate that TNF-α and TGF-β suppress CAV-1
expression in other cell types, such as ﬁbroblasts, alveolar
macrophages, and monocytes (Galdo et al, 2008; Fakhrzadeh
et al, 2008; Tourkina et al, 2010). Therefore, altered CAV-1
expression appears to be responsible for maintaining or
enhancing the vicious cycle of chronic inﬂammation in
psoriasis.
STAT proteins, in particular STAT3, have been implicated
in psoriasis. Epidermal keratinocytes in psoriatic lesions are
characterized by STAT3 activation, and increased levels of
cytokines and growth factors promote STAT3 activation (Sano
et al, 2005). For instance, IL-22, an effector cytokine
expressed by T helper type 17 cells, mediates acanthosis
through the activation of STAT3 (Zheng et al, 2007). K5.
Stat3C transgenic mice, in which keratinocytes express a
constitutively active form of STAT3, develop psoriasis-like
skin lesions, indicating that STAT3 activation is critical for the
development of psoriasis (Sano et al, 2005). Given our ﬁnding
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Figure 3. Enhanced proliferation and chemokine production in caveolin-1 (CAV-1)-decreased keratinocytes. (a) The level of keratin 16 (KRT16) expression in
CAV-1-silenced (siCAV-1) and control siRNA (siNeg) keratinocytes stimulated with IL-22 for 24 hours. Results of representative semi-quantitative PCR (left panel)
and quantitative PCR (right panel) are shown. Experiments were performed on three independent occasions in duplicate. ***Po0.001. (b) The relative levels of
C-X-C chemokine ligand 8 (CXCL8), CXCL9, C-C chemokine ligand 20 (CCL20), and IL-6 gene expression were determined by quantitative PCR in same samples
used in a. ***Po0.001. (c) Psoriasis-related cytokines may reduce CAV-1 expression in human keratinocytes. Cultured human keratinocytes were stimulated with
IL-17A, IL-22, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, epidermal growth factor (EGF), or IL-1β. After 48-hour incubation, CAV-1 gene
expression levels were determined by quantitative PCR. Experiments were performed on three independent occasions in duplicate. Phosphate-buffered saline was
used as control (Ctr). One-way analysis of variance (post hoc Dunnett), *Po0.05; **Po0.01; ***Po0.001, versus control.
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of aberrant downregulation of CAV-1 in psoriatic epidermis,
we investigated the cross-regulation between CAV-1 and
STAT3 in psoriasis. Previous studies have shown that
CAV-1 regulates cellular signaling through its CSD, and
CAV-1 binding can inhibit the nuclear translocation of various
signaling molecules (Engelman et al, 1998; Galdo et al, 2008).
In addition, binding of CAV-1 to phosphotyrosine residues of
cytokine receptors can prevent the binding of JAKs and STAT
proteins to the receptor; this suggests that CAV-1 is homo-
logous to the SOCS pseudosubstrates and functions as a
negative regulator of STAT signaling (Park et al, 2002). We
have demonstrated increased JAK2 and STAT3 phosphory-
lation in CAV-1-silenced keratinocytes. In addition, CAV-1
reduction upregulated transcriptional activity of STAT3 in
a luciferase reporter assay, revealing that activation of the
JAK/STAT pathway results from CAV-1 downregulation in
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bar=100 μm. (d) The epidermal thickness and (e) the number of inﬁltrating cells were analyzed. Graphs indicate the mean± SD of each group (n= 6). One-way
analysis of variance (post hoc Tukey), *Po0.05; **Po0.01; ***Po0.001 (IMQ+CSD vs. IMQ+Ctr).
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keratinocytes. Moreover, CAV-1-reduced keratinocytes had
increased levels of a hyperproliferation marker and psoriasis-
related cytokine/chemokines, supporting a recent report.
Yuan et al (2011) showed that STAT3 activation in CAV-1-
deﬁcient mice resulted in an enhanced inﬂammatory
response to Pseudomonas aeruginosa respiratory infection.
In that model, infected CAV-1 knockout mice expressed
higher levels of inﬂammatory cytokines, such as IL-6, TNF-α,
and IL-12a. In addition to the JAK/STAT3 signaling pathway,
other signaling cascades, such as the RAS/MAPK and
phosphoinositide-3/AKT pathways, are also activated by
psoriasis-related cytokines and growth factors. Given that
CAV-1 can also negatively regulate the RAS/MAPK and
phosphoinositide-3/AKT pathways, impaired CAV-1
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Figure 5. Suppressed inﬂammation in mice treated with imiquimod (IMQ) and CAV-1 scaffolding domain (CSD) peptide. (a) Skin sections obtained from mice
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bar=100 μm.
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expression in psoriasis may enhance signaling in these
pathways in addition to affecting STAT3 signaling.
Given the link between reduced CAV-1 expression
and psoriatic inﬂammation in human keratinocytes, we
investigated the effect of modulating CAV-1 function
in vivo. Because of the lack of good animal models for
psoriasis, we used the IMQ-induced murine model of
psoriasis-like skin inﬂammation. These mice are often used
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***Po0.001 (imiquimod+CAV-1 scaffolding domain (IMQ+CSD) vs. IMQ+Ctr). (b) CAV-1 protein levels in the epidermis of mice were analyzed by western
blotting. The CAV-1 protein levels were quantiﬁed using densitometry and expressed as the ratio of CAV-1 to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). n=3. One-way ANOVA (post hoc Tukey), *Po0.05 versus Vaseline. (c) Schematic representing the continuous psoriatic inﬂammation loop related to
reduced CAV-1 expression. Decreased levels of CAV-1 in psoriatic keratinocytes enhance signal transducer and activator of transcription 3 (STAT3) activation,
which induces keratinocyte activation and proliferation. Various keratinocyte-produced cytokines and chemokines lead to further mobilization of activated
immune cells, which in turn produce more psoriasis-related cytokines and trigger even more CAV-1 downregulation in keratinocytes. Modulating CAV-1 function
might interrupt this vicious cycle of psoriasis-related chronic inﬂammation.
Y Yamaguchi et al.
Reduced Caveolin-1 in Psoriasis Vulgaris
www.jidonline.org 2771
as a psoriasis-like model because of their psoriasis-like skin
phenotype, including the histology, cell types, and cytokine
expression (Flutter and Nestle, 2013); however, it is not a true
psoriasis model but rather an acute skin inﬂammation model.
Nevertheless, we also observed a signiﬁcant CAV-1 reduction
within the epidermal hyperplasia of these mice, similar to that
seen in psoriasis patients; therefore, we used these mice to
analyze CAV-1 function using the CSD peptide. It has
previously been shown that CSD peptide can cross the
plasma membrane as it is synthesized as a fusion with the
antennapedia internalization sequence (Bucci et al, 2000).
CSD peptide can bind to, and inhibit, different CAV-1-target
signaling molecules (Hua et al, 2003; Oka et al, 1997), and
restoration of CAV-1 function using a CSD peptide has been
suggested as a potential therapeutic strategy in ﬁbroprolifera-
tive disorders, in which CAV-1 inhibits TGF-β signaling
by promoting TGF-β receptor degradation and preventing
SMAD2 phosphorylation (Razani et al, 2001; Tourkina et al,
2008). We found that administration of CSD peptide markedly
reduced the clinical and histological signs of psoriasis in our
model mice. Furthermore, CSD peptide–treated mice had
fewer pSTAT3-positive cells in the epidermis and had
signiﬁcantly reduced expression of inﬂammatory cytokines
in the dermis, indicating that the CSD peptide exerts a
protective function against IMQ-induced inﬂammation,
although it is not clear whether it can reverse established
inﬂammation, as we administered treatment from the onset of
IMQ treatment. When we postponed the onset of CSD
treatment until day 3, when histological features of IMQ
treatment became evident (Supplementary Figure S2a online),
clinical features were also reduced and epidermal thickness
was signiﬁcantly suppressed. Further study is required to
evaluate the potential of CSD peptide as a therapeutic agent.
Interestingly, CSD treatment resulted in higher expression
of CAV-1 compared with control peptide treatment (Figure 6).
Previously, CSD peptide was not found to affect the
expression of CAV-1 per se, suggesting that CSD peptide
alters the expression of proteins downstream from CAV-1
(Tourkina et al, 2008). CSD peptide itself was not detected, as
it is only a short functional domain of CAV-1 and only mimics
CAV-1 function by interacting with signaling molecules.
It is not clear why CAV-1 levels were increased by CSD
treatment in our study; however, having observed decreased
pSTAT3-positive cells and reduced cytokine levels in CSD
peptide–treated mice, it is reasonable that reduction of
inﬂammation inhibited CAV-1 downregulation. Thus CSD
peptide may modulate cellular signaling, inhibit keratinocyte
activation, inhibit immune cell mobilization, and conse-
quently suppress the production of cytokines that trigger
CAV-1 downregulation. Thus the efﬁcacy of CSD peptide
treatment may result from an interruption of the vicious cycle
of chronic inﬂammation.
In summary, we have demonstrated that CAV-1 participates
in the pathogenesis of chronic psoriatic inﬂammation.
Signiﬁcant reduction of CAV-1 in the epidermis of psoriasis
patients may enhance STAT3 activation, keratinocyte hyper-
proliferation, and cytokine/chemokine production. Mimicking
CAV-1 function with a CSD peptide inhibited cell migration,
decreased psoriasis-related cytokines in the dermis, and
ameliorated the psoriatic phenotype in an IMQ-induced
murine model. Further studies may clarify whether the
restoration of CAV-1 function represents a therapeutic
approach for inhibiting chronic inﬂammation in psoriasis.
MATERIALS AND METHODS
Preparation of skin samples
Skin biopsy samples were collected from 18 psoriasis patients and 6
healthy volunteers. Where necessary, human or murine skin was
incubated in 3mgml− 1 dispase II overnight at 4 °C (Roche Applied
Science, Tokyo, Japan) to separate the epidermis and dermis. Cell
suspensions were prepared for western blotting and PCR analyses as
appropriate. All samples were obtained after obtaining written
informed consent, in accordance with the Declaration of Helsinki.
The study was approved by the Institutional Review Board of
Yokohama City University (Approval No: B120705021).
Cell culture and stimulation
Normal human epidermal keratinocytes (NHEKs) were purchased
from Takara Bio (Shiga, Japan) and cultured in Keratinocyte Basal
Medium (KBM) supplemented with growth factors (KGM-Gold
SingleQuots; Lonza, Walkersville, MD) or KBM alone prior to
experiments. Brieﬂy, NHEKs were cultured in KBM alone overnight
prior to stimulation with various human recombinant proteins (R&D
Systems, Minneapolis, MN): rIL-22 (200 ngml− 1), recombinant
epidermal growth factor (100 ngml−1), recombinant IL-17A (50
ngml− 1), recombinant TNF-α (25 ng ml−1), recombinant TGF-β (10
ngml− 1), and recombinant IL-1β (25 ngml− 1). Cells were harvested
24 or 48 hours after stimulation as appropriate.
Immunohistochemistry
Skin samples were embedded in parafﬁn and sectioned. Immuno-
histochemical analysis was performed as previously described
(Yamaguchi et al, 2013). Brieﬂy, sections were incubated with
antibodies against CAV-1 (BD Transduction Laboratories, Lexington,
KY), CD4 (Bioworld Technology, Louis Park, MN), CD11c (Abcam,
Cambridge, UK), pSTAT3 (Tyr705, Cell Signaling Technology,
Danvers, MA), or isotype controls. The antigen was detected using
EnVision Dual Link System-HRP or LSAB2 system-HRP, and then the
DAB chromogen or AEC+ high sensitivity substrate chromogen was
applied (Dako, Carpinteria, CA).
Semi-quantitative and qPCR
Total RNA was extracted using TRIzol and the Illustra RNAspin Mini
RNA Isolation Kit (GE Healthcare, Uppsala, Sweden). First-strand
cDNA was synthesized using the High Capacity RNA-to-cDNA Kit in
accordance with the manufacturer’s instructions (Applied Biosys-
tems, Carlsbad, CA). qPCR was performed in duplicate or triplicate
using TaqMan gene expression assays or the Thunderbird SYBR
qPCR Mix (Toyobo, Osaka, Japan) and an ABI Prism 7900 sequence
detection system in accordance with the manufacturers’ protocols.
Gene expression levels were normalized to β-actin or GAPDH as
appropriate and compared using the 2−ΔΔCt method. TaqMan probes
for human KRT16, IL6, CXCL8, CXCL9, CCL20, and β-actin were
obtained from Applied Biosystems. The primer sets used for semi-
quantitative PCR and SYBR qPCR are shown in Supplementary
Table S1 online.
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Western blotting analysis
Samples were prepared using RIPA buffer containing a protease
inhibitor cocktail as previously described (Yamaguchi et al, 2011).
Equal quantities of protein were analyzed by western blotting
using one of the following antibodies: CAV-1 (BD Transduction),
pSTAT3 (Tyr705), STAT3, pJAK2, JAK2, GAPDH (glyceraldehyde-3-
phosphate dehydrogenase; Cell Signaling), and mouse GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA). Signals were
detected using horseradish peroxidase–conjugated secondary anti-
body and ECL Prime Western Blotting Detection Reagent (GE
Healthcare).
Immunocytostaining
NHEKs were cultured in chamber slides in KBM alone overnight prior
to stimulation with human rIL-22. After 15-minute stimulation, cells
were ﬁxed and then permeabilized with 0.1% Triton X-100. After
blocking, cells were incubated with anti-CAV-1 (Thermo Fisher
Scientiﬁc, Rockford, IL) and anti-pSTAT3 or anti-STAT3 antibodies
(Cell Signaling), followed by Alexa Flour 488- or 633-conjugated
secondary IgG (Invitrogen, Grand Island, NY). Appropriate isotype
IgG was used as a control. Prolong Gold antifade reagent with DAPI
(4,6-diamidino-2-phenylindole; Life Technology, Carlsbad, CA) was
used for nuclear identiﬁcation and mounting. Images were taken
using an Olympus Fluoview 1000 microscope (Olympus America,
Melville, NY) and ﬁxed camera settings.
Coimmunoprecipitation
A total of 5× 105 NHEKs were cultured and treated with rIL-22
for 10minutes prior to collection by scraping with RIPA buffer
containing protease inhibitors. Untreated cells were used as a
control. Equal quantities of protein lysate were incubated with
2.5 μg of CAV-1 antibody (BD Transduction) or control IgG and
rotated at 4 °C overnight. Protein complexes were precipitated
using Protein A/G PLUS-Agarose Immunoprecipitation Reagent
(Santa Cruz Biotechnology), which was added for an additional
4 hours of rotation. Bound proteins were analyzed by western
blotting.
CAV-1 silencing
CAV1-speciﬁc small-interfering RNA (Stealth RNAi) was purchased
from Invitrogen. Control RNAi was used as a negative control. For
reverse transfection, 100 pM of each RNAi was added to 500 μl Opti-
MEM, and 5 μl Lipofectamine RNAiMAX2000 (Invitrogen) was added
to each well. After 20minutes, 8×104 NHEKs were seeded in KBM
containing growth factors but lacking antibiotics. Cells were cultured
for 48 hours prior to harvesting or stimulation with IL-22. The
medium was changed to KBM without growth factors 16 hours before
stimulation.
Luciferase reporter gene assay
Transcriptional activity of STAT3 was measured using the Cignal
STAT3 Reporter Kit (SA Biosciences, Valencia, CA) according to the
manufacturer’s instructions. NHEKs (8× 106 cells per well) were co-
transfected with a STAT3-responsive reporter and with CAV-1 RNAi
or control RNAi. The Cignal negative reporter was also used as
control. After 48 hours, the cells were treated with 200 ngml− 1 of
IL-22 for 1 hour. Cell lysates were subjected to luciferase activity
analysis using the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI).
Murine model of psoriasis-like skin inﬂammation
For all in vivo experiments, 6-week-old C57BL/6J female mice
(Oriental Yeast, Tokyo, Japan) were used. IMQ was used to induce
skin inﬂammation as previously described (van der Fits et al, 2009). A
daily dose of 62.5 mg of 5% IMQ cream (Beselna cream; Mochida
Pharmaceutical, Tokyo, Japan) was applied to the back skin of mice
for 7 days. Vaseline was used as control. Animal experiments were
performed in accordance with the Yokohama City University
Institutional Animal Care and Use Committee guidelines (Approval
No: F-A-13-051).
CSD peptide treatment
Peptides corresponding to the CSD (DGIWKASFTTFTVTKYWFYR)
and a scrambled control peptide (Ctr: WGIDKAFFTTSTVTYKWFRY),
fused to the antennapedia internalization sequence (RQIKIWFQN
RRMKWKK), were synthesized and dissolved in dimethyl sulfoxide.
For injection, peptides were diluted in phosphate-buffered saline,
and 100 μl of a 0.1 mM solution of the CSD or Ctr peptide was
injected intradermally into the back skin of mice following each IMQ
treatment for 7 days. Mice were euthanized by CO2 asphyxiation,
and the skin surrounding the injection site was harvested at day 8 and
used for analysis.
Measurement of skin scores, epidermal thickness, and the
number of inﬁltrating cells
The clinical skin score of mice was determined from day 1 (the ﬁrst
day of treatment) and each treatment day until day 7 using the
modiﬁed psoriasis severity index score. The degree of skin erythema,
induration, and scale were classiﬁed as follows: 0, no symptoms; 1,
mild; 2, moderate; 3, severe; or 4, very severe. Sections from parafﬁn-
embedded mouse skin samples were stained with hematoxylin and
eosin. Images were captured using a microscope (model BZ-9000;
Keyence, Osaka, Japan). For each section, the thickness of the
epidermis was measured from the stratum basale to the stratum
granulosum using BZ-II Analyzer software (Keyence). The average
value from 10 random ﬁelds of view was calculated for each mouse.
Inﬁltrated cells were also counted from 10 random ﬁelds of view of
10,000 μm2 for each mouse.
Statistical analysis
Statistical comparisons were performed using the unpaired Student’s
t-test. In some analyses, one-way analysis of variance (post hoc
Tukey or Dunnett) was used as indicated.
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